Corrigendum to “Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway”

---

H.-H. Yu, H.-C. Wang, M.-C. Hsieh, M.-C. Lee, B.-C. Su, and Y.-S. Shan, “Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway,” BioMed Research International 2022, (2022): 4246086, https://doi.org/10.1155/2022/4246086.

In the article, there is an error in Figure 2e, which was mistakenly duplicated from Figure 2d in the production process. Additionally, the Figure 2 legend contains errors. The correct Figure 2 and its accompanying legend is shown below:

(a)

(b)

(c)

(d)

(e)

Figure 2 

Exendin-4 attenuates unsaturated fatty acid–induced steatosis. (a) HepG2 cells were transfected with shLuc (nontargeting shRNA) or shLC3-1/shLC3-2 for 48 h. Subsequently, the cells were treated with OA (250 μM) or PA (250 μM) for 24 h. The cells were then treated with or without Exendin-4 (200 nM) for another 24 h. Oil Red O staining was performed. (b, c) Quantification of Oil Red O signals. (d, e) Cells were treated as described in (a); cell lysates were collected and immunoblotted with the indicated antibodies. All experiments were repeated three times with similar results.

We apologize for this error.